SCHEMBL10094260

SCHEMBL10094260

CC(C)c1cccnc1Nc1ccc2nccnc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 2/20 0.45
▸ ADRA2C P18825 2/20 0.45
▸ ALDH1A1 P00352 5/20 0.43
▸ HPGD P15428 5/20 0.43
▸ MAPT P10636 5/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ TP53 P04637 3/20 0.43
▸ CASP1 P29466 2/20 0.43
▸ CASP7 P55210 2/20 0.43
▸ SYK P43405 2/20 0.43
▸ NPC1 O15118 7/20 0.43
▸ RAB9A P51151 7/20 0.43
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ POLB P06746 4/20 0.43
▸ ADRA2B P18089 1/20 0.42
▸ ADRA1D P25100 1/20 0.42
▸ ADRA1A P35348 1/20 0.42
▸ ADRA1B P35368 1/20 0.42
▸ ABCB1 P08183 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10094258 0.87 GRM4 (0.54) ALDH1A1MAPTKDM4EHSD17B10TP53
SCHEMBL10094191 0.79 DHODH (0.51) ALDH1A1HPGDMAPTHSD17B10NPC1
SCHEMBL10094254 0.78 RAB9A (0.54) ALDH1A1HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL10094192 0.78 DHODH (0.54) ALDH1A1HPGDMAPTNPC1RAB9A
SCHEMBL10094180 0.78 NPC1 (0.47) ALDH1A1HPGDMAPTKDM4ENPC1
SCHEMBL10094166 0.75 CCNA2 (0.48) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL10094204 0.75 HPGD (0.58) ALDH1A1HPGDKDM4ESYKNPC1
SCHEMBL10094188 0.75 PIK3CA (0.53) ALDH1A1HPGDMAPTNPC1RAB9A
SCHEMBL10094278 0.74 DHODH (0.60) ALDH1A1HPGDMAPTNPC1RAB9A
SCHEMBL10094249 0.74 SYK (0.48) ALDH1A1HPGDMAPTSYKNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 — — US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 ADRA2A 839/4885ADRA2C 717/4885ALDH1A1 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback